News | December 09, 2009

Linacs to Generate Nuclear Isotopes for Canada, Not Reactors

December 9, 2009 - An expert panel reviewing Canadian medical isotope productions selected electron beam technology as a superior approach to accelerator-based isotope production.

The panel has recommended the Canadian government make an investment in linear accelerator (linac) technology to address the country’s shrinking isotope supply.

Noting significant vulnerabilities in Canada’s radioisotope technetium-99 supply (used to scan patients for cancer and heart ailments), following the May 2009 shutdown of the NRU reactor at Chalk River, the Canadian Government called on an expert panel in July 2009 to review and recommend options for securing supply and alternative production of Tc-99. Over 20 "expression of interest" proposals from North American companies were considered.

Iotron Industries, an irradiation services using electron beam technology, will provide an alternative to nuclear production, at a very competitive cost. Iotron’s technology is characterized as linac, based on MO-100 transmutation, and was specifically singled out by the Canadian Medical Isotope Review Panel as a superior approach to accelerator based isotope production.

The benefits of linac technology identified in the panel’s report are:
· Two facilities could service all of Canada’s needs
· Relatively short timeline required to first production of badly needed isotopes
· Requires a very modest price increase and is price competitive with all other options
· Generates no nuclear waste
· Capital cost is much lower than any other facilities capable of producing long lasting isotopes

The Chalk River reactor is 52 years old and supplies up to 80 percent of the medical isotopes used in Canada and 40 percent of those needed globally. Canadian doctors warn of the quickly growing risk of compromised patient diagnosis and treatment should the shortage continue into the future.

Iotron President Lloyd Scott confirms that a great deal of progress has been made by Iotrons’ research and development efforts on the high power target, extraction, purification, and recycling processes since the submission of the expression of interest in July 2009.

Iotron will commence open communication with the Canadian government next week to begin the process of initiating action on the panel’s recommendation for investment.

For more information: www.iotron.com

Related Content

ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
Overlay Init